Study to assess and establish safety of convalescent plasma (CVP) drawn from mild symptomatic COVID-19 patients. - mCCP

AIIMS0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•a)Anyone aged >18 years and <65 years;
•c)Body weight: >50 kg;
•d)Patients with complete seroconversion;
•e)Written informed consent to participate in the study.
•f)Confirmed previous SARS CoV-2 infection with mild symptomatology limited to: 1) cough, 2) fever, 3) myalgia, 4) sore throat, 5) chest pain or pressure, 6) congestion, 7) headache 8) diarrhoea, 9) nausea, and 10) loss of taste or smell.

•a)Anyone aged <18 years and >65 years;
•c)Any comorbid conditions like Diabetes mellitus (uncontrolled), Hypertension (Uncontrolled), Asthma or any other respiratory conditions;
•d)Patients of COVID-19 with moderate and/ or severe symptomatology;
•e)Patients with no seroconversion;
•f)Patients with incomplete seroconversion;
•g)Failure to obtain Written informed consent;
•h)Known cases of any malignancy (Cancer COVID-19).

发起方